Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.

To see complete record on, please visit this link

Id: NCT04433845

Organisation Name: Sheppard Pratt Health System

Overal Status: Active, not recruiting

Start Date: March 1, 2021

Last Update: October 25, 2022

Lead Sponsor: Sheppard Pratt Health System

Brief Summary: The primary objective of this study is to evaluate the efficacy of 25 mg of psilocybin under supportive conditions to adult participants with BP-II, current episode depressed, in improving depressive symptoms.

  • Treatment Resistant Depression

Total execution time in seconds: 0.51233792304993